Zhonghua yi xue za zhi
-
Zhonghua yi xue za zhi · Dec 2012
Randomized Controlled Trial Multicenter Study[Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
To evaluate the efficacy and safety of 1-year adjuvant trastuzumab (herceptin) versus 1-year non-trastuzumab observation in Chinese patients with HER2-positive early breast cancer during a median follow-up of 1 year. ⋯ One-year treatment with adjuvant trastuzumab improves disease-free survival, recurrence-free survival and distant disease-free survival in Chinese patients with HER2-positive early breast cancer.